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Abstract
Gamma-delta T-cell lymphomas are very rare and aggressive T-cell neoplasms 
with complex heterogenicity and diagnostic complexity. Gamma-delta T lympho-
cytes originate from CD4− CD8− (double negative) thymocytes in the bone marrow 
and are distinct from alpha beta subtype. Four entities of gamma-delta lymphomas 
recognized by 2016 WHO classification of lymphoid neoplasms include: hepato-
splenic Tγδ lymphoma (HSγδTL), primary cutaneous gamma-delta TCL (PCTCL), 
monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) and large granu-
lar lymphocytic leukemias (T-LGL). Extensive literature search based on small case 
series and case reports identifies few more subtypes of gamma-delta T-lymphomas 
which were not previously classified by World Health Organization. There remains a 
critical gap in our understanding of the subtypes of gamma-delta T-cell lymphomas 
and a lack of updated summarization. In this review, we summarize in detail on the 
classification, biology, heterogenicity, diagnosis, clinical behavior and treatment 
options of these rare but clinically important entities.
Keywords: gamma-delta T-cell, T cell lymphoma, non-Hodgkin lymphoma,  
T-cell receptor, hepatosplenic T cell lymphoma
1. Introduction
T/NK (natural killer) cell lymphomas are uncommon lymphomas accounting 
for about 6% of all non-Hodgkin lymphoma (NHL). B-cell lymphomas account 
for the majority being 80% and Hodgkin lymphoma accounts for 7% of NHLs in 
the United States according to the Surveillance, Epidemiology, and End Results 
program (SEER) over a 10-year period from 1997 till 2006 [1]. According to the 
updated 2016 revision of World Health Organization Classification (WHO) of 
T-cell lymphoid neoplasms, there are about 27 types of mature T and NK cell 
neoplasms. Amongst all types, gamma-delta T-cell lymphoma (γδ-TCL) accounts 
for only <1% of lymphoid tumors [2].
T lymphocytes recognize antigens through T-cell receptors (TCRs). TCRs are 
polypeptide heterodimers which mostly constitutes α and β chains and rarely γ and δ 
chains. Alpha-beta T cells (Tαβ) constitute 95% of all T cells while gamma-delta T cells 
(Tγδ) make up only a small proportion accounting to <5% of all circulating lympho-
cytes. Majority of lymphoid tissues are made of αβ T cells than γδ subtype. Gamma-
delta (γδ) subtype shows selective tropism for the red pulp of the spleen, mucosal 
tissues, gastrointestinal epithelial tissues, skin and rarely lymphoid tissue. Hence the 
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γδ T cells have a higher representation of about 30% in some epithelial-rich tissues, 
such as intestine and sinusoidal red pulp of the spleen [3]. Most of the T-cell lympho-
mas have alpha-beta TCRs while only 5% of the T-NHL’s have gamma-delta TCRs [4].
2. T-cell receptor
T-cell receptors are complex membrane proteins which are found on the surface 
of T lymphocytes through which the T cells recognize the antigens. The antigens are 
recognized as peptides linked to major histocompatibility complex (MHC) mol-
ecules [5]. T lymphocytes recognize antigens through T cell receptors (TCRs). TCRs 
are polypeptide heterodimers composed of two different protein chains. These two 
chains mostly consist of alpha (α) chain and a beta (β) chain in 95% of the cases 
whereas in 5%, these chains are composed of gamma and delta (γ/δ) chains. Alpha 
and beta chains are encoded by T-cell receptor alpha (TRA) at 14q11.2 and T-cell 
receptor beta (TRB) gene at 7q34. The gamma and delta chains are encoded by T cell 
receptor gamma locus (TRG) (7p14) and T cell receptor delta locus (TRD) (14q11.2) 
genes respectively [6]. TRαβ recognizes processed antigens presented by MHC 
proteins whereas TR γδ recognizes non-peptide antigens.
After the T cell lineage commitment is made, the progenitors make their first 
lineage decision to be either αβ or γδ. CD4− CD8− (double negative) thymocytes 
rearrange three out of four TCR loci: Tcrb, Tcrg, and Tcrd. The cells which are arrested 
Figure 1. 
Illustration of T cell development.
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in proliferation at this stage require expression of TCR to re-enter the cell cycle. If 
there is a success in an in-frame Tcrb rearrangement, TCRβ is expressed which forms 
a complex with the germline-encoded pre-TCRα (pTα) chain [3]. Increased upregula-
tion of CD4 and CD8 receptors along with increased proliferation occurs when this 
complex is expressed. Tcrq is silenced and Tcra rearrangement starts thus resulting in 
excision of Tcrd locus. CD4+ CD8+ [double positive (DP)] thymocytes express TCRαβ 
and further differentiate into CD4+ or CD8+ lineages when there is a rearrangement 
of T cell receptor alpha chain (Tcra). Progression through the DP stage is believed 
to be a hallmark of αβ lineage commitment. Thymocyte progenitors which have a 
rearrangement of Tcrg and Tcrd will express γδTCR at the cell surface. These cells also 
undergo increased proliferation but tend to avoid going through the DP stage thus 
arriving at the periphery as CD4− CD8− (or, more rarely, with CD4− CD8+ or CD4+ 
CD8−) cells. Hence the lineage toward αβ or γδ is based on the progression towards 
the DP stage [7]. See Figure 1 for illustration of T-cell development.
3. Gamma-delta T cells
Gamma-delta T lymphocytes originate from CD4− CD8− (double negative) thymo-
cytes in the bone marrow and do not need recognition by the major histocompatibility 
complex [8]. The antigenic stimulus that activates these subtype of cells is unknown. 
These lymphocytes have properties of cytotoxicity, phagocytosis [9, 10] and also play a 
major role in both innate immunity and non-specific immune responses [11–13].
There are two variable receptor regions within the T cell receptor in gamma delta T cells 
which divide them into two subtypes—Vdelta1 and Vdelta2 gamma delta T-cells [14, 15].  
These two subtypes further differ in their phenotypes and the regions of distribution 
Figure 2. 
Illustration γδ of T cell function and the roles of specific subsets. Vdelta1 T cells are more predominant in 
gastrointestinal tract and Vdelta2 cells in skin, lymphoid tissue and tonsils.
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within the body. While Vdelta1 T cells are more predominant in gastrointestinal tract, 
Vdelta2 T cells are seen mostly in skin, lymphoid tissue and tonsils. See Figure 2 for 
illustration of summary of γδ T-cell functions and the roles of specific subsets.
4. WHO 2016 revised classification
Gamma-delta T-cell lymphomas constitute a very rare and aggressive subtype of 
lymphomas with a very poor prognosis [16]. The gamma delta T-cell lymphomas were 
classified into two groups in 2008 by the World Health Organization (WHO) as hepa-
tosplenic Tγδ cell lymphoma (HSγδTL) and primary cutaneous TCL (PCTCL) [17]. 
In 2016, the WHO classification of T Tγδ cell lymphoma added few more subgroups.
As per 2016 revision of the WHO classification of lymphoid neoplasms, the four 
recognized entities of Tγδ cell lymphoma identified includes,
1. Hepatosplenic Tγδ cell lymphoma (HSγδTL)
2. Primary cutaneous gamma delta TCL (PCTCL)
a. Aggressive variant
b. Mycosis fungoides like (Indolent variant)
3. Monomorphic epitheliotropic intestinal TCL (MEITL)
4. Gamma-delta large granular lymphocytic leukemias (T-LGL)
Although the WHO classification is helpful in defining the subtypes of lympho-
mas, there are other rare variants of gamma-delta T-cell lymphomas in literature in 
the form of case reports which still remains unclassifiable. Based on an extensive 
literature search, we classify gamma delta T-cell lymphomas into the five subtypes 
as illustrated in Table 1.
1. Hepatosplenic Tγδ cell lymphoma (HSγδTL)
2. Primary cutaneous gamma-delta T-cell lymphoma (PCTCL)
a. Aggressive variant
b. Mycosis fungoides like (indolent variant)
c. Subcutaneous panniculitis-like
3. Mucosal gamma-delta T-cell lymphoma
a. Gastrointestinal
b. Nasal
c. Pulmonary
d. Laryngeal
4. Gamma-delta T-LGL
5. Nodal gamma-delta T-cell lymphoma
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5. Gene expression profiling of gamma delta lymphoma
Research studies have shown that the different molecular profiling exists 
between γδTCL and αβTCL as well as the existence of a distinct molecular signature 
in hepatosplenic gamma delta T cell lymphoma.
Kana Miyazaki et al. analyzed RNA from seven patients with gamma delta T cell 
lymphoma (four hepatosplenic, one cutaneous, one intestinal and one thyroidal) 
and 27 patients with alpha beta T cell lymphoma (11 peripheral TCL unspecified, 15 
angioimmunoblastic TCL and one hepatosplenic) using oligonucleotide microar-
rays. Based on the genetic analysis, they classified hepatosplenic γδTCL as a single 
cluster, whereas other γδTCL were more heterogeneous and were scattered within 
the αβ distribution. Gene expression profiles were compared between γδTCL and 
αβTCLs, using 291 genes. Webgestalt analysis using Gene Ontology (GO) hier-
archies for categorizing functional gene groups and Kyoto Encyclopedia of gene 
and genomes (KEGG) pathway was used for identifying signaling pathways. They 
concluded that five in γδTCL and 20 in αβTCL gene groups were expressed under 
the GO category and three γδTCL pathways and one αβTCL pathway were found 
to be altered in KEGG-signaling analyses. These studies concluded that no signa-
ture genes were shared between γδTCL and αβTCL thereby confirming different 
functional profiling between them. Genes encoding KIRs and killer cell lectin-like 
receptors were seen in four out of five γδTCL enriched GO categories and two out of 
three KEGG signaling pathways, thus becoming a very important marker in differ-
entiating γδTCL from αβTCL [18].
Table 1. 
Classification of gamma-delta T-cell lymphomas.
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6. Types of gamma delta T-cell lymphoma
6.1 Hepatosplenic Tγδ cell lymphoma (HSγδTL)
Hepatosplenic gamma delta T cell lymphoma is one of the types of gamma 
delta T-cell lymphoma with an aggressive clinical course and poor overall survival 
rates [19]. The average length of survival seems to be <16 months [20]. The unique 
feature of this type of T cell lymphoma is the extranodal involvement with a specific 
sinusoidal pattern of infiltration of the liver, red pulp of spleen and bone mar-
row [21]. It also has unique immunophenotypical and chromosomal abnormality 
distinguishing it from other subtypes of gamma delta T cell lymphomas [22].
6.1.1 Incidence and etiology
Hepatosplenic Tγδ cell lymphoma seems to be predominantly a disease of young 
age mostly affecting teenage and young adults. They represent <5% of all peripheral 
T cell lymphomas. Males are affected more than females with a male/female ratio 
of 10/1. Although chronic antigenic stimulation and immune dysregulation seems 
to be likely causative factor in the evolution of this disorder [23], most of the cases 
(72%) of HSGDTCL occurs in patients with no underlying immunosuppression. 
Only around 18% of patients have underlying immunosuppression in the form 
of either previous organ transplants, chronic steroids use, inflammatory bowel 
disease, autoimmune disorders and hematological malignancies especially of acute 
myeloid leukemia, multiple myeloma, and Hodgkin lymphoma. About 10% of the 
patients have a history of previous treatment with immunosuppressive or biologics 
especially azathioprine and infliximab [24]. There are few cases reporting associa-
tions with Epstein-Barr Virus (EBV) and hepatitis B infections in the literature [25].
6.1.2 Pathology
The histopathological feature of HSGDTL includes monomorphous infiltration 
of medium-sized lymphocytes with a moderate amount of large pale basophilic 
cytoplasm [23, 26–28]. These cells have loosely condensed nuclear chromatin with 
small inconspicuous nucleoli. Spleen shows an involvement of sinuses of red pulp 
with atrophic white pulp. Involvement of liver is predominantly in the sinusoids. 
Bone marrow involvement occurs with predominantly intrasinusoidal distribution. 
An interstitial pattern of bone marrow involvement with a shift towards blastic cells 
are features of disease progression. Lymph node involvement is very rare.
Immunophenotypic origin is from double negative CD4− CD8− cells which show 
CD2+ CD3+ CD5− CD7+, TCRγδ+ [28, 29]. NK cell markers (DC16, CD56, CD57) may 
occasionally be expressed. They also show expression of cytotoxic granule-associated 
proteins such as TIA1 and granzyme M but are negative for granzyme B and perforin 
[22, 29]. A minority of variant forms of HSGDTL shows TCR αβ expression.
The most common cytogenetic abnormality seen in HSGDTL is isochromosome 7q 
abnormality [i(7q)]. Trisomy 8 and deletion of Y chromosome are other genetic abnor-
malities sometimes encountered. The primary cytogenetic event which occurs initially 
is i(7q) while the other genomic alteration occurs when the disease progresses [30–32].
6.1.3 Molecular genetics of HSGDTL
Although isochromosome 7q is the most common chromosomal abnormality 
detected so far in HSTL, recent genomic analysis by Julio Finalet Ferreiro et al. 
identified a rare variant aberration of ring 7 [r(7)], thereby narrowing down the 
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critical 7p/7q regions and identifying the targeted genes. They did genomic and 
transcriptomic study of six i(7) (q10) and ring 7 [r(7)] cases of HSTL, thereby 
mapping the common deleted region (CDR) at 7p22.1p14.1 (34.88 Mb; 3,506,316–
38,406,226 bp) and the common gained region (CGR) at 7q22.11q31.1 (38.77 Mb; 
86,259,620–124,892,276 bp). They postulated that loss of 7p22.1p14.1 enhanced 
the expression of CHN2 (7p14.1)/b2-chimerin leading to downmodulation of the 
NFAT pathway thereby increasing proliferation. They also hypothesized that the 
multidrug resistance gene ABCB1, RUNDC3B, PPP1R9A have an increased expres-
sion with the amplification of 7q22.11q31.1, thereby providing a growth advantage 
for the tumor cells further increasing their intrinsic chemoresistance. They distin-
guished HSTL from other malignancies by identifying a set of 24 genes by doing 
gene expression profile of HSTL, including three located on chromosome 7 (CHN2, 
ABCB1, and PPP1R9A) [33].
McKinney et al. did detailed study on the whole exome sequencing of 68 HSTL 
cases and identified the commonly mutated genes including SETD2, INO80, and 
ARID1B in 62% of HSTL cases. Mutations were also identified in STAT5B (31%), 
STAT3 (9%), and PIK3CD (9%) which has targeted treatments currently. The most 
commonly silenced gene was found to be SETD (tumor suppressor gene). Cell sur-
vival in HSTL was linked to the mutations in STAT5B and PIK3CD which activates 
the critical signaling pathways [34].
6.1.4 Staging
Staging of HSGDTL is based on the physical examination, hematological and 
biochemical parameters, imaging studies including computed tomography (CT) 
and positron emission tomography (PET) scans, bone marrow biopsy and gastroin-
testinal tract examination. Experience of PET imaging in T cell lymphomas is anec-
dotal when compared to B cell lymphomas [35–37]. Ann-Arbor staging system is 
used for staging of HSGDTL like any other NHL [38]. As per this staging, HSGDTL 
is classified as stage IV disease commonly presenting with systemic symptoms, 
hepatosplenic involvement with rare occurrence of bulky disease.
6.1.5 Postulated cell of origin
HSGDTCL is believed to arise from the immature non-activated gamma-delta T 
cells (Tγδ) of Vdelta1 subtype which are predominantly seen in the gastrointestinal 
tract [39–41].
6.1.6 Clinical presentation
HSGDTL is mainly a disease of young men affecting in their second or third 
decade of life [42]. Main presenting features include systemic symptoms, hepa-
tosplenomegaly and the absence of lymphadenopathy. The presenting feature of 
HSGDTL as per literature review include cytopenia, splenomegaly, fever, weight 
loss, fatigue and easy bruising. Laboratory abnormality included anemia, throm-
bocytopenia, neutropenia, mildly elevated AST, ALT and alkaline phosphatase. 
Markedly elevated lactate dehydrogenase (LDH) is a frequently observed phenom-
enon. Fifty to 80% of cases can have peripheral neoplastic lymphocytes [20]. Very 
rarely can present with autoimmune hemolytic anemia [43]. Bone marrow involve-
ment is very frequent at diagnosis [20, 44] Cytopenia is related to bone marrow 
infiltration, hypersplenism, and cytokine-induced hemophagocytic histiocytosis 
[45]. Re-appearance of thrombocytopenia is used as an indicator of relapse of 
disease in a patient who is in complete remission. Cutaneous and mediastinal 
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involvement is very unusual. Presence of lymphadenopathy is very rare and would 
virtually rule out the possibility of HSGDTL.
6.1.7 Treatment and prognosis
There exists no consensus in the treatment of these lymphomas due to its rarity 
and limited possibility of prospective trials. Most commonly used treatment regimen 
is CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen 
with an acceptable response rate between 30 and 45%. But even with those who 
achieve complete remission, the median time to relapse remains around 4 months [22, 
46, 47]. Few other treatment options previously tried includes corticosteroids, alkyl-
ating agents, anthracycline-containing agents like CHOP/HYPERCVAD regimen, 
purine analogs and cytarabine-cisplatin combination. Few cases have reported clinical 
response with alemtuzumab combined with purine analogs but no overall survival 
benefit was noted [48–50]. But this combination causes significant hematological 
toxicity causing deeper immunosuppression and the risk of infection reactivations.
Autologous and allogeneic stem cell transplantations have been used as a 
modality of treatment with good response. There are case reports which support 
bortezomib in combination with high dose CHOP chemotherapy followed by BEAM 
autograft as well as CHOP regimen followed by high dose methotrexate, high dose 
cyclophosphamide with subsequent autograft using conditioning regimen contain-
ing etoposide, ifosfamide, and ranimustine [51]. Allogeneic stem cell transplanta-
tion has previously been tried with encouraging results but at the expense of 
treatment-related mortality. Various myeloablative conditioning regimen has been 
tried usually including total body irradiation. Relapse-free interval has been shown 
to be between 12 and 58 months after treatment of aggressive disease with allo-
geneic transplant. Relapsed/refractory disease is usually resistant to conventional 
chemotherapy and there are previous case reports of successful second allogeneic 
transplant for patients who failed the first allograft [52]. Relapse of the disease 
is usually seen in the initially involved sites but lymphadenopathy is uncommon 
which signifies the homing of these neoplastic cells.
Treatment of relapsed/refractory disease with single agents like bevacizumab, 
vorinostat, lenalidomide, bortezomib, bendamustine and etoposide has been 
reported in single cases but no large case series data exist about their efficacy 
[53–59]. HSGDTL is a very aggressive disease which is resistant to most of the con-
ventional chemotherapeutic agents. The median survival has been estimated to be 
<1 year for those treated with a CHOP-like regimen. Most of the patients do not live 
longer than 2 years [14]. Even though there is a lack of clear prognostic factors, data 
from small case series suggests male sex, lack of TCR rearrangements and failure of 
response has been shown to have negative outcomes [42]. New onset thrombocyto-
penia has been linked to the recurrence and severity of the disease in few cases [20].
6.2 Primary cutaneous gamma delta T-cell lymphoma (PCGD-TCL)
As per 2016 WHO classification of mature lymphoid, histiocytic and dendritic 
neoplasms, cutaneous T cell lymphomas are classified as subcutaneous panniculitis-
like T cell lymphoma, mycosis fungoides (MF), Sezary syndrome, primary cutane-
ous gamma delta T cell lymphomas (PCGD-TCL), lymphoid polyposis, CD30+ 
primary cutaneous anaplastic large cell lymphoma, primary cutaneous CD8+ 
aggressive epidermotropic cytotoxic T cell lymphomas, primary cutaneous acral 
CD8+ T-cell lymphoma, primary cutaneous lymphomas, not otherwise classified 
(PCTL, NOS), extranodal nasal-type NK/T-cell lymphomas and primary cutaneous 
CD4+ small/medium T-cell lymphoproliferative disorder.
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Primary cutaneous gamma delta T-cell lymphomas is a rare malignancy with 
a very aggressive course. There also exists rarer variants which have an indolent 
course as per few case reports [60]. Primary cutaneous gamma delta T-cell lympho-
mas have a preference for extremities and can present either as plaque, tumor or 
subcutaneous nodules. They do not exhibit EBV positivity and mostly have a mature 
cytotoxic phenotype.
6.2.1 Incidence and risk factors
PCGD-TCL accounts for <1% of all cutaneous TCLs [17]. It arises from clonal 
proliferation of cytotoxic gamma-delta T-cells in the skin. Mostly all cases are 
grouped as either mycosis fungoides-like or subcutaneous panniculitis-like cuta-
neous lymphomas. Generally, these mucocutaneous subtypes are not related to 
Epstein-Barr virus infections [61].
Chronic antigenic stimulation along with decreased immunity remains the 
underlying risk factor for developing this disease. Some of the other risk factors 
seem to be underlying autoimmunity, malignancy, viral hepatitis and other lym-
phoproliferative disorders.
6.2.2 Pathology
Histologically the infiltration patterns can involve epidermis, dermis and 
subcutaneous tissue. These patterns can be present separately or can be seen within 
the same lesion [23]. The presentation can be disseminated, necrotizing or ulcer-
ative. Pathological features involve angioinvasion, angiodestruction, and necrosis. 
Epidermal involvement may vary from being mild epidermotrophic to a marked 
pagetoid variety [62]. In the subcutaneous panniculitis type, infiltration with 
medium to large neoplastic cells with clumped chromatin is seen around adipose 
tissues. Occasionally blastoid cells with prominent nucleoli are noted.
The neoplastic cells usually express CD2 and CD3 and are usually negative for 
CD4 and CD8. They also express CD7, CD56 and frequently are positive for cyto-
toxic proteins like TIA-1, granzyme B, and perforin. They do not express βF1.
TCRγ expression has also been reported in other primary cutaneous TCLs espe-
cially in mycosis fungoides and lymphomatoid papulosis. Even though these lympho-
mas are CD8 negative, few cases of CD8+ PCGD-TCLs have been reported [16].
6.2.3 Molecular genetics
Neoplastic cells always express TCRγ and TCRδ genetic rearrangements. They 
are also negative for EBV encoded RNA emphasizing that EBV infection does not 
play any role in their pathogenesis [23]. PCGD-TCLs show very complex cytogenetic 
alterations which include translocations involving breakpoints at 9p21, 14q11.2, 
14q32.1 or 16q23.1. This suggests that the tumor evolvement is related to WWOX, 
TCL gene cluster, and BCL11B [63].
Other pathways involved in tumorigenesis includes pathways related to RAS, 
P13KT/MTOR, TP53 and MYC related signaling [26]. There are no characteristic 
mutations identified so far.
6.2.4 Staging
Staging involves a complete workup including hematological evaluation, bio-
chemical evaluation, gastrointestinal evaluation, bone marrow biopsy, PET CT and/
or computed tomography scans. Most commonly used staging system for PCGD-TCL 
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is the International Society for Cutaneous Lymphoma/European Organization of 
Research and Treatment of Cancer (ISCL/EORTC) TNM classification system of 
cutaneous lymphoma other than mycosis fungoides and Sezary syndrome [64].
6.2.5 Clinical presentation
Most of the cases occur in older adults with a median age of 60 years. There 
seems to be no gender preference and both sexes are equally affected [65]. PCGD-
TCL shows diffuse skin involvement with a predilection for extremities, thighs, 
and buttocks and spares the trunk. They may present either as a papule, plaque or 
nodule with ulceration and overlying epidermal necrosis. Few cases present as pan-
niculitis either with dermal or subcutaneous infiltration [61].
In one of the study gamma delta cutaneous T-cell lymphomas have been shown 
to have a poor survival when compared with alpha-beta subtype. The median 
survival for the former was 15 months whereas it was 166 months for latter. It was 
also found that patients who had subcutaneous involvement had decreased survival 
(13 months) compared to those who had epidermotrophic or dermal involvement 
(29 months). Poor prognostic factors included gamma delta phenotype, subcutane-
ous involvement, and presentation as clinical tumors [16].
Most of the patients have B symptoms like fever, weight loss, and an elevated 
LDH. Hemophagocytic syndrome is more likely with panniculitis like presentation 
[61]. Although most of the cases of PCGD-TCL is aggressive, there are also cases 
which are indolent. This indolent variety has been described previously as “ketron-
goodman type” presenting as verrucoid lesions [53]. Mucosal and extranodal 
dissemination mainly to GI tract and nasopharynx are seen [66–72]. Widespread 
dissemination is rare and involvement if spleen, liver and bone marrow are 
infrequent. Only very few cases have lymph node involvement [73]. Rare cases of 
metastasis to testis and central nervous system have been reported.
6.2.6 Treatment and prognosis
No standard treatment exists due to the rarity of this disease. Hence the treatment 
guidelines are mostly based on case reports. Most commonly used regimen remains to 
be doxorubicin-based regimen like CHOP. About 50% of the patients showed response 
but subsequently had a relapse of the disease with tumor progression and death. 
Steroids have been used with increased remission rate [74]. Low dose methotrexate 
and narrow-band ultraviolet radiation have also been used in few types of PCGDTL 
presenting as patch/plaque [75]. Bexarotene as a single agent and in combination was 
used as maintenance after CHOP-like regimen showing good response [76].
Due to the aggressive nature of the disease, autologous and allogeneic stem 
cell transplant has also been tried. In a small case series (n = 13) complete remis-
sion rate of 92% was achieved with stem cell transplant. But this study included 
alpha/beta phenotype as well which impairs the application of the results. The 
more indolent subtype remains responsive to steroids without the need for a more 
aggressive approach [60].
The overall prognosis seems to be very poor due to aggressive nature and chemo-
therapy resistance of these lymphomas. They have a median survival of 15 months 
and a 5-year overall survival is around 10% [16]. But the more indolent subtypes 
usually have slightly better prognosis when compared to aggressive subtype. Poor 
prognostic factors included subcutaneous involvement, age > 40 years, associated 
cytopenias, tumors expressing CD56, CD95 without expressing CD8, extensive 
ulcerated lesions at presentation, central nervous system (CNS) involvement and 
the presence of hemophagocytic syndrome as per the largest reported series [77, 78].
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6.3 Mucosal gamma delta TCL
This type of lymphoma affects the mucosal tract lining nasopharynx, intestine, 
breast, larynx, lung, and testis indicating the homing of these γδ T-cells. These are 
very aggressive lymphomas and due to the rarity of the disease, information regard-
ing the presentation and treatment is only from small case series.
6.3.1 Incidence and risk factors
Mucosal gamma-delta lymphoma is very rare aggressive tumor whose inci-
dence cannot be predicted due to rarity and limited literature evidence. Chronic 
antigenic stimulation along with prolonged immune suppression seems to be a 
major risk factor in the development of this disease. Patients with underlying 
hypogammaglobulinemia, selective IgA deficiency, and T cell deficiency are more 
prone to develop this disease. In one of the case series, it was found that patients 
who developed nasal lymphoma had past history of chronic sinusitis. Similarly, 
pulmonary lymphomas developed in a background of opportunistic pulmonary 
infections. Gastric and intestinal lymphomas had a predisposing factor of H. pylori 
and coeliac sprue [26, 66, 79].
6.3.2 Pathology
Morphologically they are variable in nature presenting either as small to 
medium-sized cells or as large pleomorphic variants. Occasionally cells had 
abundant clear cytoplasm with irregular nuclei with condensed chromatin. Other 
features commonly seen include angioinvasion, angiocentrism, epitheliotropism 
and necrosis [42].
Most of them express TCRγδ (δTCR1+) but are negative for TCR αβ. They com-
monly express CD2 and CD3 but did not express CD4, CD8, and CD5. CD7 may be 
variable. CD56 is expressed mostly by nasal T-cell lymphomas and are infrequent in 
other types. Since the tumor arises from activated cytotoxic T cells, there is a posi-
tive expression for T cell intracellular antigen 1 (TIA1), granzyme B, and perforin. 
EBV association has been reported in nasal, laryngeal and gastrointestinal mucosal 
gamma-delta T-cell lymphoma. EBV-encoded latent membrane protein studied by 
immunohistochemistry is found positive in these variants [42].
6.3.3 Genetic abnormality
Neoplastic cells showed clonal γ chain rearrangement showing evidence of T cell 
lineage and clonality. They show positivity for EBV encoded RNA emphasizing that 
EBV infection does play a role in their pathogenesis. No other characteristic muta-
tions have been identified so far.
6.3.4 Clinical presentation
Mucosal gamma-delta T-cell lymphomas usually have an aggressive course with 
high recurrence rate presenting both with a local and systemic disease. In one of the 
case series, the median age of the patient was 48 years. Nasal lymphomas present as 
destructive nasal lesions as well as nasal obstruction. Gastrointestinal lymphomas 
usually involve either localized or diffuse areas of the gut thereby presenting as 
peritonitis and perforation [66]. Most of the patients present with B symptoms but 
rarely have any lymphadenopathy or bone marrow involvement. Elevated LDH and 
hypogammaglobulinemia were observed in few cases [66].
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6.3.5 Treatment and prognosis
Due to the rarity of the disease, no guidelines exist. Literature evidences are 
available for treatment with CHOP-like regimen and stem cell transplantation. 
Clinical outcome is mostly associated with short overall survival. Durable remis-
sion was seen only in few cases. In a small case series of 11 patients, most of the 
patients died within 1 year and only three had some durable response lasting more 
than a year [66].
6.4 Gamma delta T-LGL
Gamma-delta T-LGL represents 2–3% of all mature lymphocytic leukemia. 
Most of the T-LGL have αβ rearrangements and are positive for CD8, CD16, CD57. 
γδ T-cell large granular lymphocytic (T-LGL) is a very rare heterogeneous disorder 
of mature lymphocytes with unique morphology and an indolent clinical course. 
Although this variant is similar to the common T-LGL, some differences exist in 
clinical presentation, immunophenotype and organ involvement.
6.4.1 Incidence and risk factors
γδ T-LGL accounts for <5% of all T-LGLs. Usually, this type of lymphoma pres-
ents in patients >50 years old. Underlying immunosuppression is an associated risk 
factor for its development. Association with rheumatoid arthritis has been reported 
in about 20% of cases of γδ T-LGL and 25% of αβ T-LGL [80–82].
6.4.2 Pathology
Neoplastic cells can be infiltrated most commonly in bone marrow and 
spleen. When present in peripheral blood, they appear as large granular lympho-
cytes with azurophilic granules. Bone marrow involvement is characterized by 
lymphoid aggregates especially in the interstitial and intrasinusoidal areas [83]. 
Splenic involvement is characterized by infiltration of small lymphocytes with 
dense chromatin mostly concentrated in the red pulp rather than the white pulp 
[84, 85].
The neoplastic cells show positivity for pan T cell antigens CD2, CD3, and CD7. 
CD5 may be variable. They are usually CD8 positive and CD4 negative but cases 
with CD8 positivity has been reported previously [80, 81, 83, 86]. They show vari-
able expression for CD16, CD56, and CD57. Cytotoxic markers like granzyme B and 
TIA-1 are seen in all cases. Flow cytometry usually shows positive expression for 
TCRγδ (δTCR1+) and is negative for TCR αβ. Immunohistochemical studies show 
TCRγ and negative for βF1 (marker for TCRβ).
6.4.3 Genetics
Neoplastic cells showed clonal γ chain rearrangement showing evidence of T cell 
lineage and clonality. Due to similar immunophenotype, especially of CD4-CD8− 
T-LGL with hepatosplenic gamma-delta T-cell lymphoma, further cytogenetic and 
FISH analysis need to be done to prove negativity for isochromosome 7q (i7q) [80, 83].
6.4.4 Clinical presentation
B symptom is common particularly with fever and fatigue predominating. The 
lab abnormality includes anemia, neutropenia, and thrombocytopenia with some 
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cases presenting with increased severity. Not all patients present with lymphocy-
tosis and occasionally lymphopenia is also observed. The peripheral smear shows 
large lymphocytes with prominent azurophilic granules in patients presenting 
with lymphocytosis. Splenomegaly is a common finding, but lymphadenopathy 
is rare. Bone marrow involvement is present mostly and shows predominantly an 
interstitial or less commonly intrasinusoidal pattern of infiltration. Associated 
autoimmune disorders like autoimmune hemolytic anemia (AIHA), immune 
thrombocytopenic purpura (ITP), rheumatoid disorder, pure red cell aplasia is also 
commonly observed [83].
6.4.5 Treatment and prognosis
The clinical course is mostly indolent. T-LGL generally is a chronic disorder with a 
good 10-year survival of 80% with around half of the patients not requiring any ther-
apy [80, 81, 83, 87]. Spontaneous regression has been seen in few cases [88, 89]. The 
common reason for therapy remains to be low blood counts followed by hemolysis and 
splenomegaly. Several treatments like methotrexate, cyclophosphamide, cyclosporine, 
fludarabine, pentostatin either alone or in combination with steroids have been tried 
[90–93]. More resistant or advanced disease needs cytotoxic chemotherapy. Clinical 
course can be aggressive especially if they express CD56 antigen [94]. Splenectomy 
was also done as part of the treatment of ITP associated with this disorder.
6.5 Nodal gamma delta TCL
Nodal gamma delta TCL is a very rare subtype within gamma delta T-cell lym-
phomas. Very limited information is available in the literature due to the extreme 
rarity of this variant. So far only six cases of nodal gamma delta lymphomas have 
been reported. Usually, the presentation is in the form of disseminated nodal 
involvement.
6.5.1 Incidence and risk factors
Incidence difficult to predict due to the rarity of the disease. Chronic antigenic 
stimulation associated with immunosuppression plays a major role in the pathogen-
esis. Few case reports also suggest the role of EBV in lymphomagenesis.
6.5.2 Pathology
Neoplastic cells are very variable. They can present as a diffuse pleomorphic 
proliferation of small to medium-sized lymphoid cells with an irregular nucleus 
and moderate cytoplasm. They can also present as large pleomorphic cells or 
anaplastic or angioimmunoblastic like cells [42]. In one case report describing two 
cases of nodal gamma delta T-cell lymphoma, nodal preservation was noted in the 
first case whereas complete destruction of architecture was observed in the other 
[95]. The second case presented with lymphadenopathy and hepatosplenomegaly 
and had infiltration of lymphoid cells in the intrasinusoidal area of the lymph 
node. Predominant involvement of T zones was observed in one case [96]. Hence 
there may be two different patterns of presentation with diffuse pleomorphic 
involvement mimicking classical αβ T-cell lymphoma or hepatosplenic involvement 
mimicking hepatosplenic gamma-delta lymphoma [97].
The neoplastic cells express CD2, CD3, CD43, CD45. They also exhibit positiv-
ity for TIA-1, granzyme B and displayed a gamma delta phenotype (deltaTCR1+, 
Vdelta1+, Vdelta2−, Vdelta3−, betaF1−).
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6.5.3 Genetic abnormality
The genotypic analysis shows TCR gamma-chain gene rearrangement pattern. 
The neoplastic cells also show expression of the latent membrane protein-1 by 
immunohistochemistry and EBV-encoded small RNAs by in situ hybridization. EBV 
positivity was also observed in tumor recurrence as reported in one case report [98]. 
A complex cytogenetic abnormality is seen in few cases, but no specific cytogenetic 
abnormality exists for this variant.
6.5.4 Clinical presentation
Patients most commonly present with lymphadenopathy. Usually, there is a 
past history of immunosuppression. In one case report, nodal gamma delta T-cell 
lymphoma presented post renal transplant in one case and after cytomegalovirus 
(CMV) infection in another case. Bone marrow infiltration and hepatospleno-
megaly have also been reported [95].
6.5.5 Treatment and prognosis
This subtype is very resistant to conventional chemotherapy and has a very poor 
prognosis. Patients presenting with this type of lymphoma died within a short time 
after diagnosis [95].
7. Conclusion
Even though WHO 2016 classification of lymphoid malignancies recognizes four 
entities of gamma delta lymphomas, few more subtypes have been reported in litera-
ture which remains unclassified. These clinically important lymphomas pose a clini-
cal challenge in diagnosis and management due to rarity and critical gap in consensus 
of treatment. Combination of clinical picture, morphology, immunophenotyping, 
molecular techniques are used in combination due to the diagnostic difficulties of 
these lymphomas. The poor prognosis associated with these subtypes is related to 
the rapidly evolving clinical picture and refractoriness to standard chemotherapies. 
Cytarabine combined with platinum-based regimen followed by stem cell transplan-
tation seems to be the optimal management option for eligible patients. Encouraging 
prompt reporting of these rarer entities needs to be encouraged to further advance 
our understanding thus allowing newer perspective in the management.
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